Back

Targets, Trials, and Trajectories: Transforming ATTR-CM Care

This interactive activity focuses on optimizing management of transthyretin amyloid cardiomyopathy (ATTR-CM) by bridging upstream pathophysiology with practical clinical evidence. Learners explore the step-by-step amyloid cascade, differentiating the mechanisms of TTR stabilizers, RNA silencers, and emerging disease-modifying therapies that shift clinical expectations toward amyloid regression. Subsequent modules touch on pivotal long-term extension data alongside real-world cohort evidence to translate critical trial signals into timely, as well as a cognitive and management approach to progress, an evolving topic in ATTR-CM management.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

No specific specialties targeted.

Pricing

Free

Reported to ACCME by the provider

  • Online course / module
  • Credit · Up to 0.5 credits
  • Commercial Support
  • Available from
    Oct 15, 2026
  • Last day to claim credit
    Oct 16, 2027 1 year left